Bronchodilator therapies for severe asthma

E.D. Bateman, L-P. Boulet

Source: Eur Respir Monogr 2011; 51: 253-267
Disease area: Airway diseases

Congress or journal article abstractFull text journal article

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
E.D. Bateman, L-P. Boulet. Bronchodilator therapies for severe asthma. Eur Respir Monogr 2011; 51: 253-267

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Cough variant asthma treated with bronchodilators, without inhaled corticosteroids
Source: Annual Congress 2009 - From cough to sound analysis of breathing
Year: 2009

The role of bronchodilator treatment in the prevention of exacerbations of COPD
Source: Eur Respir J 2012; 40: 1545-1554
Year: 2012



lnhaled long-acting beta-agonists as an inhaled corticosteroid-sparing agent for chronic asthma in adults
Source: Eur Respir J 2005; 26: Suppl. 49, 124s
Year: 2005

Role of tiotropium in reducing exacerbations in COPD patients when added to long-acting beta2-agonists (LABA) and inhaled corticosteroids (ICS): The OUTPUL study
Source: Annual Congress 2013 –Treatment and adherence to treatment of respiratory disease
Year: 2013


Children with mild asthma: do they benefit from inhaled corticosteroids?
Source: Eur Respir J 2002; 20: 1470-1475
Year: 2002



Cessation of long-acting beta2-agonist in children with persistent asthma on inhaled corticosteroids
Source: Eur Respir J 2016; 48: 558-560
Year: 2016


Effect of oral prednisolone on the bronchoprotective effect of formoterol in patients with persistent asthma
Source: Eur Respir J 2001; 17: 374-379
Year: 2001



The effect on mortality of adding inhaled corticosteroids to long-acting bronchodilators for COPD: A focus on the frequent exacerbator phenotype
Source: International Congress 2015 – COPD and lung function: risk factors and outcomes
Year: 2015

Effects of ciclesonide and fluticasone on cortisol secretion in patients with persistent asthma
Source: Eur Respir J 2009; 33: 1277-1286
Year: 2009



Comparison of the efficacy and safety of long-acting anticholinergic and a combination of inhaled steroids and long-acting beta-2 agonist in moderate chronic obstructive pulmonary disease
Source: Annual Congress 2013 –COPD drugs: new findings
Year: 2013

Comparison of asthma treatment given in addition to inhaled corticosteroids on airway inflammation and responsiveness
Source: Eur Respir J 2006; 27: 1144-1151
Year: 2006



Treatment of acute asthma
Source: Eur Respir Mon 2012; 56: 172-187
Year: 2012


Nebulizer therapy with budesonide in addition to systemic corticosteroids in acute severe asthma
Source: Eur Respir J 2004; 24: Suppl. 48, 541s
Year: 2004

The effects of nebulised bronchodilators and corticosteroids treatment compared with inhaled drug therapy for moderate COPD patients
Source: Eur Respir J 2004; 24: Suppl. 48, 290s
Year: 2004

Salmeterol treatment improves corticosteroid responsivness in patients with corticosteroid-insensitive severe asthma
Source: Annual Congress 2005 - Improving asthma control in the harder-to-reach population
Year: 2005


RPL554, an inhaled PDE3/4 inhibitor, causes comparable bronchodilation to high dose nebulised salbutamol in asthmatics with fewer systemic effects
Source: International Congress 2016 – Novel mechanisms and treatment modalities in asthma
Year: 2016

In chronic obstructive pulmonary disease, a combination of ipratropium and long-acting beta2-agonists is more effective than either agent alone
Source: Eur Respir J 2001; 18: Suppl. 33, 211s
Year: 2001

24-h duration of the novel LABA vilanterol trifenatate in asthma patients treated with inhaled corticosteroids},
Source: Eur Respir J 2012; 40: 570-579
Year: 2012



Clinically important deteriorations in COPD as a measure of response to dual and mono bronchodilator therapy with and without inhaled corticosteroids
Source: International Congress 2015 – New data on established treatments for COPD
Year: 2015


Individual and differential treatment responses to once-daily long acting bronchodilators, glycopirronium and indacaterol, and combination of both drugs in the patients with moderate or severe COPD
Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments
Year: 2014